Neurocrine Biosciences, Inc. (NASDAQ:NBIX) will announce its earnings results after the market closes on Tuesday, October 31st. Analysts expect the company to announce earnings of ($0.49) per share for the quarter.
Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Thursday, August 3rd. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.01). The firm had revenue of $6.34 million during the quarter, compared to analyst estimates of $0.61 million. During the same period in the previous year, the business posted ($0.46) earnings per share. On average, analysts expect Neurocrine Biosciences to post $-2.42 EPS for the current fiscal year and $-1.84 EPS for the next fiscal year.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) opened at 62.14 on Friday. The stock has a 50 day moving average price of $59.64 and a 200 day moving average price of $52.51. Neurocrine Biosciences, Inc. has a one year low of $37.35 and a one year high of $63.77. The firm’s market cap is $5.48 billion.
NBIX has been the subject of several recent research reports. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and set a $70.00 target price on shares of Neurocrine Biosciences in a research note on Wednesday, July 5th. BMO Capital Markets increased their target price on shares of Neurocrine Biosciences from $75.00 to $84.00 and gave the stock an “outperform” rating in a research note on Friday, August 4th. Cowen and Company reiterated an “outperform” rating and set a $65.00 target price (up previously from $60.00) on shares of Neurocrine Biosciences in a research note on Wednesday, August 9th. BidaskClub upgraded shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research note on Wednesday, August 9th. Finally, Piper Jaffray Companies set a $68.00 target price on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a research note on Thursday, August 24th. Two analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $69.31.
In other news, insider Christopher Flint Obrien sold 6,925 shares of Neurocrine Biosciences stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $61.04, for a total transaction of $422,702.00. Following the completion of the sale, the insider now directly owns 55,898 shares in the company, valued at approximately $3,412,013.92. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Haig P. Bozigian sold 26,250 shares of Neurocrine Biosciences stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $1,575,000.00. Following the sale, the insider now owns 144,601 shares of the company’s stock, valued at $8,676,060. The disclosure for this sale can be found here. In the last 90 days, insiders sold 123,846 shares of company stock valued at $7,004,150. 4.80% of the stock is owned by insiders.
A hedge fund recently raised its stake in Neurocrine Biosciences stock. The Manufacturers Life Insurance Company grew its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 7.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,665 shares of the company’s stock after acquiring an additional 193 shares during the period. The Manufacturers Life Insurance Company ‘s holdings in Neurocrine Biosciences were worth $123,000 at the end of the most recent reporting period.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
What are top analysts saying about Neurocrine Biosciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Neurocrine Biosciences Inc. and related companies.